This week, we will discuss the HOPE trial - no not that one - the one in dialysis that was a LBCT in 2024. Should we look beyond analgesics to non-pharmacological options more seriously?
ACEing the management of advanced CKD
BPROAD: Sprinting down the BP Road in Diabetes
Potassium Rollercoaster Heartbreak
FLOZINATing to the Future- Long Term Effects of Empagliflozin in Patients with CKD
The Ondansetron Ballet: Torsades de Pointes
Re”FINE”ing the role of non steroidal MRAs in Cardio Kidney Metabolic syndrome
Playing It Safe: Can Felzartamab Fill the Gap in AMR Treatment?
The pressure is on! Unravelling the ESPRIT of Intensive vs Standard BP Control
This week, we will discuss the ongoing saga of blood pressure targets in patients with hypertension. This time its ESPRIT (Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing Risk of Vascular Events) making a case for case for intensive BP control in most hypertensive individuals, including those with a history of diabetes and stroke.




















